Article
09 Jul 2026
Medicare Payment Cuts For 340B Drugs, Take Two: CMS Proposes 37% Cut To 340B Hospitals
AUTHORS CONTENT
Article
10 Jun 2026
No Surprises In Dispute Resolution: Final Rule Improves IDR Process For Providers
Article
12 Feb 2026
OIG Issues New Guidance On DTC Drug Sales And AKS Risk
Article
05 Jan 2026
Federal Court Puts 340B Rebate Model On Hold
Article
15 Aug 2025
HRSA Unveils Pilot Program To Allow Limited 340B Drug Rebate Models
Article
30 Apr 2025
Arkansas Restricts PBM Ownership Of Pharmacies And Limits Manufacturers' Use Of Limited Distribution Networks
Article
23 Dec 2024
340B Drug Rebate Models: Status And Litigation Update
Article
28 May 2024
D.C. Circuit Becomes Second Federal Appeals Court To Allow Restrictions On 340B Contract Pharmacies
Article
20 May 2024
Key Takeaways From 2024 Asembia Specialty Pharmacy Summit
Article
14 Feb 2024
CMS & HHS Withdraw Appeal To Recent Copay Accumulator Federal District Court Decision: 2020 Accumulator Rule Still In Effect
Article
08 Nov 2023
Court Guts 340B Program "Patient" Definition, Opening Door To More 340B Use
Article
30 Oct 2023
HRSA Clarifies Use Of 340B Drugs In New Hospital Clinics, Ends COVID "Waiver"
Article
13 Sep 2023
Court Strikes Down Federal Surprise Billing QPA Calculation Rules, Continuing Pause On Arbitrations
Article
01 Sep 2023
CMS Announces 10 Drugs Selected For Medicare Negotiation In 2026
Article
13 Jul 2023
CMS Proposes $9 Billion Refund To 340B Hospitals And Reductions In Future Payments To All Hospitals For Non-Drug Services